Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage

被引：0

作者：

Koga, F. ^{[1
]}

Shirakawa, T. ^{[2
]}

Shimokawa, M. ^{[3
]}

Otsuka, T. ^{[4
]}

Shimokawa, H. ^{[5
]}

Nakazawa, J. ^{[6
]}

Oda, H. ^{[7
]}

Takeshita, S. ^{[8
]}

Kawaguchi, Y. ^{[9
]}

Arita, S. ^{[10
]}

Taguchi, H. ^{[11
]}

Sakai, T. ^{[12
]}

Nishikawa, K. ^{[13
]}

Arima, S. ^{[14
]}

Ueda, Y. ^{[15
]}

Kawahira, M. ^{[16
]}

Sakae, T. ^{[17
]}

Ide, Y. ^{[18
]}

Mizuta, T. ^{[19
]}

Mitsugi, K. ^{[20
]}

机构：

[1] Saga Ken Med Ctr Koseikan, Dept Hepatobiliary & Pancreatol, Saga, Japan

[2] Karatsu Higashimatsuura Med Assoc Med Ctr, Internal Med Dept, Saga, Japan

[3] Yamaguchi Univ, Dept Biostat, Grad Sch Med, Ube, Japan

[4] Minato Med Clin, Internal Med, Fukuoka, Japan

[5] JCHO Japan Community Healthcare Org, Kyushu Hosp, Dept Hematol Oncol, Kitakyushu, Fukuoka, Japan

[6] Kagoshima City Hosp, Dept Med Oncol, Kagoshima, Japan

[7] Saiseikai Kumamoto Hosp, Div Integrat Med Oncol, Kumamoto, Japan

[8] Japanese Red Cross, Dept Gastroenterol, Nagasaki Genbaku Hosp, Nagasaki, Japan

[9] Asakura Med Assoc Hosp, Dept Gastroenterol, Asakura, Japan

[10] Miyazaki Prefectural Miyazaki Hosp, Internal Med & Chemotherapy, Miyazaki, Japan

[11] Imamura Gen Hosp, Dept Gastroenterol, Kagoshima, Japan

[12] Natl Hosp Org, Dept Med Oncol, Kumamoto Med Ctr, Kumamoto, Japan

[13] Oita Univ, Dept Med Oncol & Hematol, Fac Med, Yufu, Japan

[14] Kagoshima Univ, Digest & Lifestyle Dis, Kagoshima, Japan

[15] Japanese Red Cross, Dept Hematol & Oncol, Kumamoto Hosp, Kumamoto, Japan

[16] Kagoshima Kouseiren Hosp, Dept Gastroenterol, Kagoshima, Japan

[17] Saiseikai Sendai Hosp, Dept Gastroenterol, Satsumasendai, Japan

[18] Saga Hosp, Natl Hosp Org, Dept Internal Med, Saga, Japan

[19] Fujikawa Hosp, Dept Internal Med, Saga, Japan

[20] Sasebo Kyosai Hosp, Dept Med Oncol, Sasebo, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.287

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

152P

引用

页码：S1534 / S1534

页数：1

共 35 条

[1] Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Kusano, W.
Arita, S.
Shimokawa, M.
Otsuka, T.
Shimokawa, H.
Nakazawa, J.
Koga, F.
Oda, H.
Takeshita, S.
Kawaguchi, Y.
Taguchi, H.
Sakai, T.
Nishikawa, K.
Arima, S.
Ueda, Y.
Kawahira, M.
Sakae, T.
Shirakawa, T.
Mizuta, T.
Mitsugi, K.
ANNALS OF ONCOLOGY, 2023, 34 : S1537 - S1537
[2] A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer
Kodama, Tomoko
Imajima, Takashi
Shimokawa, Mototsugu
Otsuka, Taiga
Kawahira, Masahiro
Nakazawa, Junichi
Hori, Takeshi
Shibuki, Taro
Arima, Shiho
Ido, Akio
Miwa, Keisuke
Okabe, Yoshinobu
Koga, Futa
Ueda, Yujiro
Kubotsu, Yoshihito
Shimokawa, Hozumi
Takeshita, Shigeyuki
Nishikawa, Kazuo
Komori, Azusa
Otsu, Satoshi
Hosokawa, Ayumu
Sakai, Tatsunori
Sakai, Kenji
Oda, Hisanobu
Kawahira, Machiko
Arita, Shuji
Honda, Takuya
Taguchi, Hiroki
Tsuneyoshi, Kengo
Kawaguchi, Yasunori
Fujita, Toshihiro
Sakae, Takahiro
Shirakawa, Tsuyoshi
Mizuta, Toshihiko
Mitsugi, Kenji
SCIENTIFIC REPORTS, 2024, 14 (01):
[3] Impact of biliary drainage for pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil and folinic acid
Nishikawa, Kazuo
Kubotsu, Yoshihito
Shimokawa, Mototsugu
Otsuka, Taiga
Shibuki, Taro
Nakazawa, Junichi
Arima, Shiho
Miwa, Keisuke
Koga, Futa
Ueda, Yujiro
Shimokawa, Hozumi
Takeshita, Shigeyuki
Hosokawa, Ayumu
Sakai, Tatsunori
Oda, Hisanobu
Arita, Shuji
Kawahira, Machiko
Shiraawa, Tsuyoshi
Mizuta, Toshihiko
Mitsugi, Kenji
ANNALS OF ONCOLOGY, 2023, 34 : S1400 - S1400
[4] Efficacy and safety of nanoliposomal irinotecan plus fluorouracil and folinic acid after irinotecan-based chemotherapy in patients with advanced pancreatic cancer: Results of the retrospective part of the NAPOLEON-2 study.
Kawaguchi, Yasunori
Aikawa, Tomomi
Shimokawa, Mototsugu
Otsuka, Taiga
Shibuki, Taro
Nakazawa, Junichi
Arima, Shiho
Miwa, Keisuke
Koga, Futa
Ueda, Yujiro
Kubotsu, Yoshihito
Shimokawa, Hozumi
Takeshita, Shigeyuki
Nishikawa, Kazuo
Hosokawa, Ayumu
Oda, Hisanobu
Sakai, Tatsunori
Shirakawa, Tsuyoshi
Mizuta, Toshihiko
Mitsugi, Kenji
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 705 - 705
[5] Multicenter observational study of nanoliposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Final retrospective results.
Imajima, Takashi
Shirakawa, Tsuyoshi
Shimokawa, Mototsugu
Otsuka, Taiga
Shibuki, Taro
Nakazawa, Junichi
Arima, Shiho
Miwa, Keisuke
Koga, Futa
Kubotsu, Yoshihito
Ueda, Yujiro
Hosokawa, Ayumu
Takeshita, Shigeyuki
Shimokawa, Hozumi
Komori, Azusa
Oda, Hisanobu
Sakai, Tatsunori
Arita, Shuji
Mizuta, Toshihiko
Mitsugi, Kenji
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 706 - 706
[6] A real-world prospective analysis of the relationship between nanoliposomal irinotecan and fluorouracil with folinic acid and neutropenia in patients with pancreatic cancer (NAPOLEON-2 study, NN-2401).
Shirakawa, Tsuyoshi
Araki, Tomonori
Shimokawa, Mototsugu
Otsuka, Taiga
Nakazawa, Junichi
Shimokawa, Hozumi
Koga, Futa
Oda, Hisanobu
Takeshita, Shigeyuki
Arima, Shiho
Arita, Shuji
Kawaguchi, Yasunori
Nishikawa, Kazuo
Taguchi, Hiroki
Jikuya, Kenichi
Sakai, Tatsunori
Ueda, Yujiro
Sakae, Takahiro
Mizuta, Toshihiko
Mitsugi, Kenji
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 762 - 762
[7] A multicenter observational study of liposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Retrospective
Imajima, T.
Shirakawa, T.
Shimokawa, M.
Otsuka, T.
Shibuki, T.
Nakazawa, J.
Arima, S.
Miwa, K.
Okabe, Y.
Koga, F.
Kubotsu, Y.
Ueda, Y.
Hosokawa, A.
Takeshita, S.
Shimokawa, H.
Komori, A.
Kawahira, M.
Oda, H.
Sakai, K.
Arita, S.
Mizuta, T.
Mitsugi, K.
ANNALS OF ONCOLOGY, 2022, 33 : S289 - S290
[8] Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)
Araki, Tomonori
Hayashi, Kohei
Shimokawa, Mototsugu
Otsuka, Taiga
Sonoda, Yuki
Honda, Takuya
Shibuki, Taro
Nakazawa, Junichi
Arima, Shiho
Miwa, Keisuke
Koga, Futa
Ueda, Yujiro
Kubotsu, Yoshihito
Shimokawa, Hozumi
Takeshita, Shigeyuki
Nishikawa, Kazuo
Komori, Azusa
Otsu, Satoshi
Hosokawa, Ayumu
Sakai, Tatsunori
Oda, Hisanobu
Kawahira, Machiko
Arita, Shuji
Taguchi, Hiroki
Tsuneyoshi, Kengo
Fujita, Toshihiro
Sakae, Takahiro
Kawaguchi, Yasunori
Shirakawa, Tsuyoshi
Mizuta, Toshihiko
Mitsugi, Kenji
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
[9] Nanoliposomal irinotecan with fluorouracil and folinic acid, S-1 alone, or FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine plus nabpaclitaxel: A pooled analysis of NAPOLEON-1 and NAPOLEON-2
Otsuka, T.
Shirakawa, T.
Shimokawa, M.
Shibuki, T.
Nakazawa, J.
Arima, S.
Miwa, K.
Koga, F.
Kubotsu, Y.
Ueda, Y.
Hosokawa, A.
Takeshita, S.
Shimokawa, H.
Komori, A.
Kawahira, M.
Oda, H.
Sakai, T.
Arita, S.
Mizuta, T.
Mitsugi, K.
ANNALS OF ONCOLOGY, 2022, 33 : S1473 - S1473
[10] Real-world evidence of nanoliposomal irinotecan and fluorouracil with folinic acid in patients with unresectable or recurrent pancreatic cancer: Final results of a multicenter observational study
Shinohara, Yudai
Shirakawa, Tsuyoshi
Shimokawa, Mototsugu
Otsuka, Taiga
Shimokawa, Hozumi
Nakazawa, Junichi
Koga, Futa
Oda, Hisanobu
Takeshita, Shigeyuki
Arima, Shiho
Arita, Shuji
Kawaguchi, Yasunori
Nishikawa, Kazuo
Taguchi, Hiroki
Jikuya, Kenichi
Sakai, Tatsunori
Ueda, Yujiro
Sakae, Takahiro
Mizuta, Toshihiko
Mitsugi, Kenji
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 721 - 721

← 1 2 3 4 →